Global Drug Repurposing
At cognitive, a dedicated team has worked on this report, we have disclosed one of the team member involved in the publication and client consultation process for your reference. You can initiate the discussion her via Book an appointment
At cognitive, our research analyst works closely with Drug Repurposing market experts to validate the gathered data and have the expert's opinion available for our clients. You can book a consultation call with our research analyst and industry experts on board (Subject to time availability and paid consultation services)
The base year for the analysis is 2025. Historical data has been considered for the period from 2022 to 2025. The year 2026 is considered as the estimated base for forecasting, with projections covering the period from 2026 to 2034. When we deliver the report that time we updated report data till the purchase date.
From the database of Cognitive, this is an unique identification number of reports and it will also have different reports associated with it.
Report edition's total number of pages for pdf format (Approximate)
Rating and review received by the reader or subscriber of the said report.
Athenaeum Visualization Dashboard: Access your purchased data/Report/Service through a sophisticated, interactive interface. The Athenaeum Dashboard allows you to preview data/reports and store them in a customizable dashboard, enabling you to filter metrics and uncover deeper trends specific to your enterprise needs.
PDF Access: To ensure the highest level of data integrity and confidentiality, your premium report editions are delivered as password-protected PDF files. These are securely shared via email and remain accessible within your dedicated Athenaeum account for future reference.
Versatile Multi-Format Export (Excel & MS Word): We provide the flexibility to integrate our research directly into your internal workflows. Upon request, relevant quantitative data and qualitative insights from your purchased reports can be provided in fully editable Microsoft Excel and Word formats.
Multiple Cloud Accounts: Benefit from a dedicated, encrypted cloud account that ensures your market intelligence is available on-demand. Access your research from any device, at any time, and from any location. Multiple Accounts facilitating seamless collaboration across your collegue or whole organization.
Athenaeum AI Assistant(Value-Added Service): Elevate your research capabilities with Athenaeum AI Assistant, our proprietary 24/7 research assistant. Equivalent in depth to a dedicated research analyst, this AI-driven tool provides round-the-clock data support and instant insights to help you navigate complex market landscapes in real-time.
As Cognitive a market research and consulting firm, we can provide Drug Repurposing market Analysis and consultation services with the help of our data collection processes and Proprietary research methodology called Full Truth. We have in-house team of research analysts and network of industry experts on board. In fact, we provided high-impact consualtion services to the listed client in competitior analysis. As an extension of our bespoke consulting engagements, we also provide access to Proprietary datasets of market analysis publish, making authoritative industry intelligence accessible to the public domain.
Drug Repurposing Market Analysis 2026
Proprietary Database, Market Surveys, Strategic Consultation & Advisory Services, Industry & Competitive Intelligence. along with Report Access and Athenaeum Dashboard Subscription — Revenue, Volume, Production, Trade Analysis, value chain and supply chain analysis, Market Size, Share, Forecast, Drivers, Trends, Growth Opportunities, ESG and more.
| Data Timeline | Historical Data: 2022-2025 | Base Year: 2025 | Forecast Period: 2026-2034 |
|---|---|
| By Approach Type Outlook: Segment Analysis | Disease-centric approach, Target-centric approach, Drug-centric approach |
| By Disease Indication Outlook: Segment Analysis | Oncology, CNS Diseases, Neurodegenerative Diseases, Others (Rare Disorders, etc.) |
| By End-user Outlook: Segment Analysis | Hospitals & Clinics, Ambulatory Surgery Diseases, Others (Research Institutes, etc.) |
|---|---|
| Regions & Countries Analysis |
|
Share your contact details to receive free updated sample copy/pages of the recently published edition of Drug Repurposing Market Report 2025.
Global Drug Repurposing Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top 10 Countries Drug Repurposing Market Analysis includes Ranking, Market Size, Revenue in USD Million/Billion, Market Volume Unit
Top 10 Countries Analysis of Drug Repurposing Market Share Distribution
According to Cognitive Market Research, the global Drug Repurposing Market size will be USD 759.2 million in 2025. It will expand at a compound annual growth rate (CAGR) of 15.60% from 2025 to 2033.
- North America held the major market share for more than 37% of the global revenue with a market size of USD 280.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.4% from 2025 to 2033.
- Europe accounted for a market share of over 29% of the global revenue with a market size of USD 220.17 million.
- APAC held a market share of around 24% of the global revenue with a market size of USD 182.21 million in 2025 and will grow at a compound annual growth rate (CAGR) of 17.6% from 2025 to 2033.
- South America has a market share of more than 3.8% of the global revenue with a market size of USD 28.85 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2025 to 2033.
- Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 30.37 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2033.
- Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 16.70 million in 2025. It will grow at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2033.
- Oncology therapeutic area is the fastest growing segment of the Drug Repurposing industry
Market Drivers:
|
Market Restrains:
|
Market Trends:
|
| Market Size | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global Drug Repurposing Market Sales Revenue | xxxx | xxxx | $ 2421.13 Million | 15.6% |
| North America Drug Repurposing Market Sales Revenue | xxxx | $ 280.9 Million | $ 768.2 Million | 13.4% |
| United States Drug Repurposing Market Sales Revenue | xxxx | $ 221.63 Million | xxxx | 13.2% |
| Canada Drug Repurposing Market Sales Revenue | xxxx | $ 33.71 Million | xxxx | 14.2% |
| Mexico Drug Repurposing Market Sales Revenue | xxxx | $ 25.56 Million | xxxx | 13.9% |
| Europe Drug Repurposing Market Sales Revenue | xxxx | $ 220.17 Million | $ 623.7 Million | 13.9% |
| United Kingdom Drug Repurposing Market Sales Revenue | xxxx | $ 36.99 Million | xxxx | 14.7% |
| France Drug Repurposing Market Sales Revenue | xxxx | $ 20.26 Million | xxxx | 13.1% |
| Germany Drug Repurposing Market Sales Revenue | xxxx | $ 43.59 Million | xxxx | 14.1% |
| Italy Drug Repurposing Market Sales Revenue | xxxx | $ 18.93 Million | xxxx | 13.3% |
| Russia Drug Repurposing Market Sales Revenue | xxxx | $ 34.13 Million | xxxx | 12.9% |
| Spain Drug Repurposing Market Sales Revenue | xxxx | $ 18.05 Million | xxxx | 13% |
| Sweden Drug Repurposing Market Sales Revenue | xxxx | $ 6.83 Million | xxxx | 14% |
| Denmark Drug Repurposing Market Sales Revenue | xxxx | $ 4.62 Million | xxxx | 13.7% |
| Switzerland Drug Repurposing Market Sales Revenue | xxxx | $ 3.3 Million | xxxx | 13.6% |
| Luxembourg Drug Repurposing Market Sales Revenue | xxxx | $ 2.64 Million | xxxx | 14.2% |
| Rest of Europe Drug Repurposing Market Sales Revenue | xxxx | $ 30.82 Million | xxxx | 13.2% |
| Asia Pacific Drug Repurposing Market Sales Revenue | xxxx | $ 182.21 Million | $ 666.5 Million | 17.6% |
| China Drug Repurposing Market Sales Revenue | xxxx | $ 76.53 Million | xxxx | 17.1% |
| Japan Drug Repurposing Market Sales Revenue | xxxx | $ 25.14 Million | xxxx | 16.1% |
| South Korea Drug Repurposing Market Sales Revenue | xxxx | $ 21.86 Million | xxxx | 16.7% |
| India Drug Repurposing Market Sales Revenue | xxxx | $ 18.22 Million | xxxx | 19.5% |
| Australia Drug Repurposing Market Sales Revenue | xxxx | $ 9.47 Million | xxxx | 16.9% |
| Singapore Drug Repurposing Market Sales Revenue | xxxx | $ 3.64 Million | xxxx | 17.9% |
| Taiwan Drug Repurposing Market Sales Revenue | xxxx | $ 7.11 Million | xxxx | 17.4% |
| South East Asia Drug Repurposing Market Sales Revenue | xxxx | $ 12.03 Million | xxxx | 18.4% |
| Rest of APAC Drug Repurposing Market Sales Revenue | xxxx | $ 8.2 Million | xxxx | 17.4% |
| South America Drug Repurposing Market Sales Revenue | xxxx | $ 28.85 Million | $ 85.8 Million | 14.6% |
| Brazil Drug Repurposing Market Sales Revenue | xxxx | $ 12.35 Million | xxxx | 15.2% |
| Argentina Drug Repurposing Market Sales Revenue | xxxx | $ 4.85 Million | xxxx | 15.5% |
| Colombia Drug Repurposing Market Sales Revenue | xxxx | $ 2.57 Million | xxxx | 14.4% |
| Peru Drug Repurposing Market Sales Revenue | xxxx | $ 2.37 Million | xxxx | 14.8% |
| Chile Drug Repurposing Market Sales Revenue | xxxx | $ 2.08 Million | xxxx | 14.9% |
| Rest of South America Drug Repurposing Market Sales Revenue | xxxx | $ 4.64 Million | xxxx | 13.7% |
| Middle East Drug Repurposing Market Sales Revenue | xxxx | $ 30.37 Million | $ 92.3 Million | 14.9% |
| Qatar Drug Repurposing Market Sales Revenue | xxxx | $ 2.43 Million | xxxx | 14.2% |
| Saudi Arabia Drug Repurposing Market Sales Revenue | xxxx | $ 10.69 Million | xxxx | 15.2% |
| Turkey Drug Repurposing Market Sales Revenue | xxxx | $ 2.43 Million | xxxx | 15.5% |
| UAE Drug Repurposing Market Sales Revenue | xxxx | $ 6.26 Million | xxxx | 15.4% |
| Egypt Drug Repurposing Market Sales Revenue | xxxx | $ 1.82 Million | xxxx | 14.7% |
| Rest of Middle East Drug Repurposing Market Sales Revenue | xxxx | $ 6.74 Million | xxxx | 14.1% |
| Africa Drug Repurposing Market Sales Revenue | xxxx | $ 16.7 Million | $ 52.2 Million | 15.3% |
| Nigeria Drug Repurposing Market Sales Revenue | xxxx | $ 1.34 Million | xxxx | 15.5% |
| South Africa Drug Repurposing Market Sales Revenue | xxxx | $ 5.88 Million | xxxx | 16.2% |
Drug Repurposing Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Drug Repurposing Market Report Description
Introduction of the Drug Repurposing Market
The drug repurposing Market involves exploring existing drugs for new therapeutic indications, offering a faster, cost-effective alternative to traditional drug development. This Market is driven by the need for more efficient treatments for chronic, rare, and complex diseases. It benefits from advancements in AI, biotechnology, and growing collaboration between pharmaceutical companies and research institutions. The Market is expanding rapidly, with increasing investments in repurposing efforts due to the lower cost, reduced development time, and the potential to address unmet medical needs. This growth is expected to continue as technology evolves.
In May 2025, Algernon is set to acquire NoBrainer Imaging Centers, Inc. as part of its strategic move to establish specialized Alzheimer’s diagnostic and treatment medical clinics. These clinics will feature cutting-edge PET scan technology aimed at enhancing early detection and treatment of Alzheimer’s disease. The acquisition reflects Algernon’s commitment to advancing medical solutions in neurology. By integrating innovative imaging technology, the company aims to improve patient outcomes and drive progress in Alzheimer’s care. ”https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/218/algernon-to-acquire-nobrainer-imaging-centers-inc---plans”
Drug Repurposing Market Size
Market Dynamics of Drug Repurposing Market
Key Drivers for Drug Repurposing Market
Harnessing the Power of Artificial Intelligence to Accelerate Drug Repurposing and Transform Pharmaceutical Innovation:
The use of Artificial Intelligence (AI) in drug repurposing is transforming pharmaceutical research by discovering new uses for existing drugs faster and more precise. AI can process and analyze massive datasets—such as genetic, clinical, and chemical data—to identify promising drug-disease matches. This drastically cuts down the time and cost of drug development, which traditionally takes many years and requires significant investment. As AI continues to gain traction, its growing role in drug discovery reflects the industry's recognition of its ability to streamline processes and improve research outcomes?. In February 2025, Artificial intelligence is reshaping drug discovery by significantly improving speed, efficiency, and precision.
Rising Demand for Effective Treatments for Rare and Chronic Diseases:
The increasing prevalence of rare and chronic diseases is driving significant growth in the drug repurposing market. As these conditions often have limited treatment options, pharmaceutical companies are exploring existing drugs for new indications. Repurposing allows for quicker, cost-effective solutions compared to developing new drugs. The demand for effective therapies for these diseases continues to rise, prompting more investments and collaborations focused on repurposing existing drugs. This shift is expected to accelerate as companies seek to address unmet medical needs and improve patient outcomes.
Key Restraint Factor for the Drug Repurposing Market
Intellectual Property and Patent Issues as Key Challenges in Drug Repurposing Development:
Intellectual property (IP) and patent issues pose significant challenges to drug repurposing. Existing drugs are often protected by patents, making it difficult for companies to explore new therapeutic uses. The complexity of patent laws, including variations across regions, can create barriers to repurposing, especially when patents remain active in certain markets. This can lead to disputes and delays in development, limiting the commercial incentives for repurposing drugs. These IP challenges hinder the growth of the drug repurposing market by complicating the legal and financial aspects of the process.
Scientific and Biological Complexity:
Mechanisms of action may vary from the initial intent. Achieving optimal dosing necessitates thorough re-evaluation. Stratifying patients presents significant challenges. These scientific obstacles demand meticulous navigation.
Key Trends for Drug Repurposing Market
AI-Driven Target Identification:
Deep learning algorithms forecast new drug-disease combinations. Network pharmacology illustrates multi-target impacts. These methodologies reveal previously neglected applications. Computational techniques are becoming commonplace.
Non-Profit and Academic Initiatives:
Collaborations between public and private sectors distribute compound libraries. Open-source platforms gather repurposing concepts from the community. These cooperative frameworks expedite discoveries. They are especially advantageous for research on rare diseases.
We have various report editions of Drug Repurposing Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Impact of Trump Tariffs on the Drug Repurposing Market
Trump's tariffs on pharmaceutical imports raise the cost of essential raw materials and APIs, which are crucial for manufacturing drugs. These higher costs can make it more expensive for companies to develop and produce repurposed drugs, slowing down progress in the drug repurposing market.
The tariffs disrupt established global supply chains, affecting the timely delivery of materials and finished products. For drug repurposing efforts, delays in the availability of necessary ingredients can hinder clinical trials and development timelines.
With tariffs increasing the cost of imported medicines and components, pharmaceutical companies may pass these higher costs onto consumers. This could make repurposed drugs more expensive for patients, limiting access to affordable treatment options and affecting market demand.?
Many repurposed drugs are generic versions of established treatments, which are heavily dependent on affordable imported APIs. Tariffs can increase production costs for generic drugs, potentially leading to higher prices or reduced availability, ultimately limiting the effectiveness of repurposing strategies.
Competitive Landscape of the Drug Repurposing Market
The competitive landscape of the drug repurposing market is evolving rapidly, with key players focusing on leveraging AI, machine learning, and advanced analytics to accelerate the identification of new drug indications. Major pharmaceutical companies, along with biotech startups, are intensifying efforts to repurpose existing drugs for complex diseases, aiming to reduce development costs and timelines. Collaborations and strategic partnerships are also increasing as companies seek to enhance their research capabilities and market reach. This dynamic environment is fostering innovation and driving competition among industry leaders.
In June 2024, Excelra and AsedaSciences entered into a strategic co-marketing agreement to offer scientists a unified, user-friendly platform for small molecule toxicity assessment. This collaboration aims to streamline the evaluation process, providing researchers with an efficient tool for assessing drug safety. By combining their expertise, both companies seek to enhance the capabilities available to scientists in the field of toxicity research. The partnership will enable more accessible and effective solutions for assessing the safety of small molecules. ”https://www.excelra.com/news/asedasciences-partners-with-excelra-for-gostar/" In April 2025, Novartis has reached an agreement to acquire Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company specializing in microRNA therapeutics. Regulus’ leading asset, faburden, targets miR-17 and shows potential as a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition aligns with Novartis' focus on renal disease and will enhance its expertise in this therapeutic area. The deal strengthens Novartis' portfolio by incorporating innovative approaches to treating kidney diseases. ”https://www.novartis.com/news/media-releases/novartis-acquire-regulus-therapeutics-and-farabursen-investigational-microrna-inhibitor-treat-adpkd-most-common-genetic-cause-renal-failure"
Top Companies Market Share in Drug Repurposing Industry: (In no particular order of Rank)
| Companies | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Algernon Pharmaceuticals | xxxx | xxxx | xxxx | xxxx |
| Biovista Inc. | xxxx | xxxx | xxxx | xxxx |
| Celentyx Ltd. | xxxx | xxxx | xxxx | xxxx |
| ChemBio Discovery Inc. | xxxx | xxxx | xxxx | xxxx |
| Chord Therapeutics SA | xxxx | xxxx | xxxx | xxxx |
| Excelra | xxxx | xxxx | xxxx | xxxx |
| Fios Genomics Ltd. | xxxx | xxxx | xxxx | xxxx |
| Lantern Pharma Inc. | xxxx | xxxx | xxxx | xxxx |
| Novartis AG | xxxx | xxxx | xxxx | xxxx |
| Paradigm Biopharmaceuticals Limited | xxxx | xxxx | xxxx | xxxx |
| Predictive Oncology | xxxx | xxxx | xxxx | xxxx |
| Segue Therapeutics | xxxx | xxxx | xxxx | xxxx |
| LLC | xxxx | xxxx | xxxx | xxxx |
| Teva Pharmaceutical Industries Ltd. | xxxx | xxxx | xxxx | xxxx |
*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)
Request Any Company Profile for Preview Purpose OR Data Validation!
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of the Drug Repurposing Market
Which Region Dominates the Drug Repurposing Market in 2025?
According to Cognitive Market Research, North America dominates the drug repurposing Market due to its well-established healthcare infrastructure, significant investments in research and development, and the presence of leading pharmaceutical companies and academic institutions. The region benefits from advanced technological capabilities, particularly in AI and data analytics, which are crucial for accelerating drug repurposing efforts. Additionally, favourable regulatory frameworks and strong intellectual property protections encourage innovation. North America's large patient population and focus on addressing unmet medical needs further bolster its dominance in the Market.
Which Region is Expanding at the Fastest CAGR?
The Asia-Pacific region is the fastest-growing Market for drug repurposing, driven by rapid advancements in healthcare infrastructure and growing investment in biotechnology. Countries like China, India, and Japan are increasingly adopting AI and big data analytics to enhance drug discovery processes. The rising burden of chronic and rare diseases, combined with the need for cost-effective healthcare solutions, is accelerating the demand for repurposed drugs. Furthermore, governments in the region are introducing favourable policies and incentives, boosting the growth of the drug repurposing market in Asia-Pacific.
The current report Scope analyzes Drug Repurposing Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
- Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
- Africa (East Africa, West Africa, North Africa, South Africa)
Drug Repurposing Market Share (%) by Region (2022-2034)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
North America Drug Repurposing Market Analysis
According to Cognitive Market Research, the global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which North America held the major market share of more than 37% of the global revenue with a market size of USD 280.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.4% from 2025 to 2033.
United State Drug Repurposing Market size is USD 221.63 million in 2025
According to Cognitive Market Research, the US had a major share in the Drug Repurposing Market with a market size of USD 221.63 million in 2025 and is projected to grow at a CAGR of 13.2% during the forecast period. US is dominant due to strong R&D infrastructure and major pharma presence.
Canada Drug Repurposing Market size is USD 33.71 million in 2025
The Canadian Drug Repurposing Market had a market share of USD 33.71 million in 2025 and is projected to grow at a CAGR of 14.2% during the forecast period. Canada is the fastest growing, driven by supportive regulations and rising biotech investments.
Mexico Drug Repurposing Market size is USD 25.56 million in 2025
The Mexico Drug Repurposing Market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 25.56 million in 2025..
Europe Drug Repurposing Market Analysis
According to Cognitive Market Research, The global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which Europe held the market share of more than 29% of the global revenue with a market size of USD 220.17 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.9% from 2025 to 2033.
United Kingdom Drug Repurposing Market size is USD 36.99 million in 2025
The United Kingdom Drug Repurposing Market had a market share of USD 36.99 million in 2025 and is projected to grow at a CAGR of 14.7% during the forecast period. UK is the fastest growing due to increased funding and focus on rare disease repurposing.
France Drug Repurposing Market size is USD 20.26 million in 2025
The France Drug Repurposing Market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD 20.26 million in 2025.
Germany Drug Repurposing Market size is USD 43.59 million in 2025
According to Cognitive Market Research, the German Drug Repurposing Market size was valued at USD 43.59 million in 2025 and is projected to grow at a CAGR of 14.1% during the forecast period. Germany is dominant with strong pharmaceutical manufacturing and research capabilities.
Italy Drug Repurposing Market size is USD 18.93 million in 2025
The Italy Drug Repurposing Market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD 18.93 million in 2025.
Russia Drug Repurposing Market size is USD 34.13 million in 2025
The Russia Drug Repurposing Market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 34.13 million in 2025
Spain Drug Repurposing Market size is USD 18.05 million in 2025
The Spain Drug Repurposing Market is projected to witness growth at a CAGR of 13.0% during the forecast period with a market size of USD 18.05 million in 2025
Sweden Drug Repurposing Market size is USD 6.83 million in 2025
The Sweden Drug Repurposing Market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 6.83 million in 2025.
Denmark Drug Repurposing Market size is USD 4.62 million in 2025
The Denmark Drug Repurposing Market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 4.62 million in 2025
Switzerland Drug Repurposing Market size is USD 3.30 million in 2025
The Switzerland Drug Repurposing Market is projected to witness growth at a CAGR of 13.6% during the forecast period, with a market size of USD 3.30 million in 2025.
Luxembourg Drug Repurposing Market size is 2.64 million in 2025
The Luxembourg Drug Repurposing Market is projected to witness growth at a CAGR of 14.2% during the forecast period, with a market size of USD 2.64 million in 2025.
Rest of Europe Drug Repurposing Market size is USD 30.82 million in 2025
The Rest of Europe's Drug Repurposing Market is projected to witness growth at a CAGR of 12.6% during the forecast period, with a market size of USD 30.82 million in 2025.
Asia Pacific Drug Repurposing Market Analysis
According to Cognitive Market Research, the global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which APAC held the market share of around 24% of the global revenue with a market size of USD 182.21 million in 2025 and will grow at a compound annual growth rate (CAGR) of 17.6% from 2025 to 2033.
China Drug Repurposing Market size is USD 76.53 million in 2025
The China Drug Repurposing Market size was valued at USD 76.53 million in 2025 and is projected to grow at a CAGR of 17.1% during the forecast period. China is dominant in the drug repurposing Market with strong government backing and clinical research infrastructure.
Japan Drug Repurposing Market size is USD 25.14 million in 2025
The Japan Drug Repurposing Market is projected to witness growth at a CAGR of 16.1% during the forecast period, with a market size of USD 25.14 million in 2025
South Korea Drug Repurposing Market size is USD 21.86 million in 2025
The South Korea Drug Repurposing Market had a market share of USD 21.86 million in 2025 and is projected to grow at a CAGR of 16.7% during the forecast period.
India Drug Repurposing Market size is USD 18.22 million in 2025
The Indian Drug Repurposing Market is projected to witness growth at a CAGR of 19.5% during the forecast period, with a market size of USD 18.22 million in 2025. India is the fastest growing in the drug repurposing Market due to affordable R&D and expanding pharma capabilities.
Australia Drug Repurposing Market size is USD 9.47 million in 2025
The Australian Drug Repurposing Market is projected to witness growth at a CAGR of 16.9% during the forecast period, with a market size of USD 9.47 million in 2025.
Singapore Drug Repurposing Market size is USD 3.64 million in 2025
The Singapore Drug Repurposing Market is projected to witness growth at a CAGR of 17.9% during the forecast period, with a market size of USD 3.64 million in 2025.
Taiwan Drug Repurposing Market size is USD 7.11 million in 2025
The Taiwan Drug Repurposing Market is projected to witness growth at a CAGR of 17.4% during the forecast period, with a market size of USD 7.11 million in 2025.
South East Asia Drug Repurposing Market size is USD 12.03 million in 2025
The South East Asia Drug Repurposing Market is projected to witness growth at a CAGR of 18.4% during the forecast period, with a market size of USD 12.03 million in 2025.
Rest of APAC Drug Repurposing Market size is USD 8.20 million in 2025
The Rest of APAC Drug Repurposing Market is projected to witness growth at a CAGR of 17.4% during the forecast period, with a market size of USD 8.20 million in 2025.
South America Drug Repurposing Market Analysis
According to Cognitive Market Research, the global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which South America held the market share of around 3.8% of the global revenue with a market size of USD 28.85 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2025 to 2033.
Brazil Drug Repurposing Market size is USD 12.35 million in 2025
The Brazil Drug Repurposing Market size was valued at USD 12.35 million in 2025 and is projected to grow at a CAGR of 15.2% during the forecast period. Brazil is dominant in the drug repurposing Market with a large healthcare infrastructure and research collaborations.
Argentina Drug Repurposing Market size is USD 4.85 million in 2025
Argentina's Drug Repurposing Market had a market share of USD 4.85 million in 2025 and is projected to grow at a CAGR of 15.5% during the forecast period. Argentina is the fastest growing in the drug repurposing Market due to increasing clinical trials and governmental support for innovation.
Colombia Drug Repurposing Market size is USD 2.57 million in 2025
Colombia Drug Repurposing Market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 2.57 million in 2025
Peru Drug Repurposing Market size is USD 2.37 million in 2025
Peru Drug Repurposing Market is projected to witness growth at a CAGR of 14.8% during the forecast period, with a market size of USD 2.37 million in 2025.
Chile Drug Repurposing Market size is USD 2.08 million in 2025
Chile Drug Repurposing Market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 2.08 million in 2025
Rest of South America Drug Repurposing Market size is USD 4.64 million in 2025
The Rest of South America's Drug Repurposing Market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 4.64 million in 2025.
Middle East Drug Repurposing Market Analysis
According to Cognitive Market Research, the global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which the Middle East held the major market share of around 4% of the global revenue with a market size of USD 30.37 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.9% from 2025 to 2033.
Qatar Drug Repurposing Market size is USD 2.43 million in 2025
The Qatar Drug Repurposing Market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 2.43 million in 2025. Qatar leads in drug repurposing with strong healthcare infrastructure and demand for specialized treatments.
Saudi Arabia Drug Repurposing Market size is USD 10.69 million in 2025
The Saudi Arabia Drug Repurposing Market is projected to witness growth at a CAGR of 15.2% during the forecast period, with a market size of USD 10.69 million in 2025.
Turkey Drug Repurposing Market size is USD 2.43 million in 2025
The Turkey Drug Repurposing Market is projected to witness growth at a CAGR of 15.5% during the forecast period, with a market size of USD 2.43 million in 2025. Turkey is rapidly growing in drug repurposing due to rising R&D investments and government support.
UAE Drug Repurposing Market size is USD 6.26 million in 2025
The UAE Drug Repurposing Market is projected to witness growth at a CAGR of 15.4% during the forecast period, with a market size of USD 6.26 million in 2025.
Egypt Drug Repurposing Market size is USD 1.82 million in 2025
The Egypt Drug Repurposing Market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 1.82 million in 2025.
Rest of the Middle East Drug Repurposing Market size is USD 6.74 million in 2025
The Rest of the Middle East Drug Repurposing Market is projected to witness growth at a CAGR of 14.1% during the forecast period, with a market size of USD 6.74 million in 2025.
Africa Drug Repurposing Market Analysis
According to Cognitive Market Research, the global Drug Repurposing Market size was estimated at USD 759.2 Million, out of which Africa held the major market share of around 2.20% of the global revenue with a market size of USD 16.70 million in 2025 and will grow at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2033.
Nigeria Drug Repurposing Market size is USD 1.34 million in 2025
The Nigeria Drug Repurposing Market is projected to witness growth at a CAGR of 15.5% during the forecast period, with a market size of USD 1.34 million in 2025. Drug Repurposing Market sales flourish due to the adoption of 60 GHz frequency bands for consumer and enterprise use.
South Africa Drug Repurposing Market size is USD 5.88 million in 2025
The South Africa Drug Repurposing Market is projected to witness growth at a CAGR of 16.2% during the forecast period, with a market size of USD 5.88 million in 2025. South Africa is the fastest-growing country with strong local pharmaceutical R&D and industry expansion.
Rest of Africa Drug Repurposing Market size is USD 9.49 million in 2025
The Rest of Africa Drug Repurposing Market is projected to witness growth at a CAGR of 14.5% during the forecast period, with a market size of USD 9.49 million in 2025. Africa is dominant in drug repurposing due to global collaborations and focus on affordable treatments.
Author's Conclusion
Conclusion
- The global Drug Repurposing Market will expand significantly by 15.60% CAGR between 2025 and 2033.
- The Disease-centric approach is the dominant category in drug repurposing as it focuses on identifying treatments based on disease characteristics, allowing quicker application of existing drugs to conditions with unmet medical needs.
- Oncology is the dominant disease indication in the drug repurposing Market due to the high global cancer burden and the urgent need for cost-effective, fast-track treatment options using existing drugs.
Author's Detail
Supriya YadavResearch Analyst
LinkedIn | Profile | Book Appointment
Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.
Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.
As a Research Analyst, I bring over two years of experience in market research, data analysis, and market estimation. I specialize in turning complex datasets into meaningful insights that help businesses identify opportunities, understand market dynamics, and make confident, growth-focused decisions.
My expertise spans across analyzing industry trends, forecasting market potential, mapping competitive landscapes, and studying consumer behavior to deliver actionable recommendations. With an MBA in Marketing and Finance, I combine strong analytical skills with strategic thinking, ensuring that every project I work on contributes real value to clients.
I am passionate about using research to uncover patterns, anticipate shifts, and deliver insights that drive measurable business impact. My goal is to continuously learn, innovate, and provide data-driven solutions that empower clients to succeed in a competitive environment.
Frequently Asked Questions (FAQs)
Reviews
Drug Repurposing Market Segmentation Analysis from 2022 till 2034
Global Drug Repurposing Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Drug Repurposing Industry growth. Drug Repurposing market has been segmented with the help of its By Approach Type Outlook:, By Disease Indication Outlook: By End-user Outlook:, and others. Drug Repurposing market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
How are Segments Performing in the Global Drug Repurposing Market?
Drug Repurposing Market Approach Type Segment Analysis
According to Cognitive Market Research, the disease-centric approach is currently the dominant category in the drug repurposing market. This approach focuses on identifying new therapeutic uses for existing drugs based on specific diseases, especially those with unmet medical needs like cancer, neurological disorders, and rare diseases. By leveraging existing drugs to treat a range of diseases, this method allows for quicker, cost-effective treatments. Researchers can focus on diseases with high prevalence or complex pathologies, making the disease-centric approach highly effective for addressing significant health challenges and improving patient outcomes.
The target-centric approach is the fastest-growing segment in the drug repurposing market. This strategy involves focusing on specific biological targets, such as proteins or genes, and identifying existing drugs that may interact with these targets to treat various diseases. With the rise of precision medicine and advancements in biotechnology, the target-centric approach is gaining traction due to its ability to tailor treatments to individual molecular profiles. The increasing use of AI and machine learning to predict target-disease relationships further accelerates its growth, making it a key focus in modern drug repurposing efforts.
Drug Repurposing Market Share (%) by By Approach Type Outlook: in 2022-2034
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Drug Repurposing Industry. Request a Free Sample PDF!
Drug Repurposing Market Disease Indication Segment Analysis
According to Cognitive Market Research, Oncology is the dominant category in the drug repurposing market. Cancer remains one of the most significant global health challenges, driving substantial investments in drug development. Repurposing existing drugs for oncology-related indications allows for faster clinical development and potentially lower costs compared to traditional cancer drug discovery. Many existing medications, originally designed for other conditions, have shown promise in targeting cancer cells. This has led to the increasing adoption of the disease-centric approach in oncology, positioning it as the leading focus area in the drug repurposing market.
Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s disease, represent the fastest-growing category in the drug repurposing market. The rising global prevalence of these diseases, coupled with limited treatment options, is driving interest in repurposing existing drugs. With the advancement of technologies like AI and biomarkers, researchers are uncovering potential repurposed treatments more quickly. Given the ageing global population and the complex nature of neurodegenerative diseases, this segment is experiencing rapid growth as the search for effective therapies intensifies.
Drug Repurposing Market Share (%) by By Disease Indication Outlook: in 2022-2034
2022
2026
2034
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
By End-user Outlook: Segmentation Analysis from 2022 till 2034: Hospitals & Clinics, Ambulatory Surgery Diseases, Others (Research Institutes, etc.)
Drug Repurposing Market End-user Segment Analysis
According to Cognitive Market Research, Hospitals and clinics are the dominant end-user category in the drug repurposing market. These healthcare settings are the primary locations where drug repurposing is implemented for patient care. Hospitals and clinics are where patients with a wide range of diseases, including chronic and rare conditions, receive treatment. The ability to quickly introduce repurposed drugs in these environments, especially for conditions like cancer or neurodegenerative diseases, makes hospitals and clinics a central focus for drug repurposing efforts. Their established infrastructure and patient base contribute to their dominance in the Market.
Ambulatory surgery centres (ASCs) are the fastest-growing end-user category in the drug repurposing market. These centres are becoming more prominent due to their ability to provide cost-effective outpatient procedures and treatments. ASCs are increasingly adopting repurposed drugs to manage conditions requiring surgical interventions, such as certain cancers and orthopaedic conditions. As the demand for more affordable and efficient healthcare grows, ambulatory surgery centres are rapidly expanding their role in administering repurposed drugs, making them a key growth driver in the drug repurposing market.
- Hospitals & Clinics
- Ambulatory Surgery Diseases
- Others (Research Institutes
- etc.)
Drug Repurposing Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| By Approach Type Outlook: | Disease-centric approach, Target-centric approach, Drug-centric approach |
| By Disease Indication Outlook: | Oncology, CNS Diseases, Neurodegenerative Diseases, Others (Rare Disorders, etc.) |
| By End-user Outlook: | Hospitals & Clinics, Ambulatory Surgery Diseases, Others (Research Institutes, etc.) |
| List of Competitors | Algernon Pharmaceuticals, Biovista Inc., Celentyx Ltd., ChemBio Discovery Inc., Chord Therapeutics SA, Excelra, Fios Genomics Ltd., Lantern Pharma Inc., Novartis AG, Paradigm Biopharmaceuticals Limited, Predictive Oncology, Segue Therapeutics, LLC, Teva Pharmaceutical Industries Ltd. |
Chapter 1 2026 Geopolitical Outlook - Drug Repurposing Market Detailed Analysis
-
1.1 Global Power Realignment & Strategic Alliances
-
1.2 Geopolitical Risk Landscape & Conflict Hotspots
-
1.3 International Trade Relations & Market Access Environment
-
1.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
-
1.5 Supply Chain Resilience, Localization & Resource Nationalism
-
1.6 Technology Sovereignty & Digital Geopolitics
-
1.7 Strategic Implications for Investment, Growth & Market Entry
This chapter isn't just about technology; it’s about certainty. We show you how AI is being used in leading industries so you can apply those same 'High-Speed' and 'High-Accuracy' principles to your own market strategy
Chapter 2 AI's Impact on Market - Detailed Qualitative Analysis
-
2.1 Competitive Landscape Disruption & Strategic Shifts
-
2.2 AI-Driven Transformation of Industry Value Chain
-
2.3 Evolution of Business Models & Revenue Streams
-
2.4 Operational Efficiency & Cost Structure Transformation
-
2.5 Product, Service & Innovation Acceleration
-
2.6 Customer Behavior & Demand Evolution
-
2.7 Future Outlook: AI-Led Market Evolution & Strategic Implications
This chapter will help you gain GLOBAL Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review Global Drug Repurposing Market Split by various segments and Geographical Split.
Chapter 3 Global Market Analysis
-
3.1 Global Drug Repurposing Revenue Market Size, Trend Analysis 2022 - 2034
-
3.2 Global Drug Repurposing Volume Market Sales, Trend Analysis 2022 - 2034
-
3.3 Global Drug Repurposing Market Size By Regions 2022 - 2034
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
3.3.1 Global Drug Repurposing Revenue Market Size By Region
-
3.3.2 Global Drug Repurposing Volume Market Sales By Region
-
-
3.4 Global Drug Repurposing Market Size By By Approach Type Outlook: 2022 - 2034
-
3.4.1 Disease-centric approach Market Size
-
3.4.2 Target-centric approach Market Size
-
3.4.3 Drug-centric approach Market Size
-
-
3.5 Global Drug Repurposing Volume Market Sales By By Approach Type Outlook: 2022 - 2034
-
3.5.1 Disease-centric approach Sales Volume
-
3.5.2 Target-centric approach Sales Volume
-
3.5.3 Drug-centric approach Sales Volume
-
-
3.6 Global Drug Repurposing Market Size By By Disease Indication Outlook: 2022 - 2034
-
3.6.1 Oncology Market Size
-
3.6.2 CNS Diseases Market Size
-
3.6.3 Neurodegenerative Diseases Market Size
-
3.6.4 Others (Rare Disorders Market Size
-
3.6.5 etc.) Market Size
-
-
3.7 Global Drug Repurposing Volume Market Sales By By Disease Indication Outlook: 2022 - 2034
-
3.7.1 Oncology Sales Volume
-
3.7.2 CNS Diseases Sales Volume
-
3.7.3 Neurodegenerative Diseases Sales Volume
-
3.7.4 Others (Rare Disorders Sales Volume
-
3.7.5 etc.) Sales Volume
-
-
3.8 Global Drug Repurposing Market Size By By End-user Outlook: 2022 - 2034
-
3.8.1 Hospitals & Clinics Market Size
-
3.8.2 Ambulatory Surgery Diseases Market Size
-
3.8.3 Others (Research Institutes Market Size
-
3.8.4 etc.) Market Size
-
-
3.9 Global Drug Repurposing Volume Market Sales By By End-user Outlook: 2022 - 2034
-
3.9.1 Hospitals & Clinics Sales Volume
-
3.9.2 Ambulatory Surgery Diseases Sales Volume
-
3.9.3 Others (Research Institutes Sales Volume
-
3.9.4 etc.) Sales Volume
-
-
3.10 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
3.11 Executive Summary Global Market (2021 vs 2025 vs 2033)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
3.11.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
-
3.11.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
-
3.11.3 Global Market Revenue Split By By Approach Type Outlook:
-
3.11.4 Global Volume Market Split By By Approach Type Outlook:
-
3.11.5 Global Market Revenue Split By By Disease Indication Outlook:
-
3.11.6 Global Volume Market Split By By Disease Indication Outlook:
-
3.11.7 Global Market Revenue Split By By End-user Outlook:
-
3.11.8 Global Volume Market Split By By End-user Outlook:
-
3.11.9 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review North America Drug Repurposing Market Split by various segments and Country Split.
Chapter 4 North America Market Analysis
-
4.1 North America Drug Repurposing Market Outlook
-
4.1.1 North America Drug Repurposing Market Size 2022 - 2034
-
4.1.2 North America Drug Repurposing Volume Market Sales 2022 - 2034
-
4.1.3 North America Drug Repurposing Market Size By Country 2022 - 2034
-
4.1.4 North America Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
4.1.5 North America Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
4.1.5.1 North America Disease-centric approach Market Size
-
4.1.5.2 North America Target-centric approach Market Size
-
4.1.5.3 North America Drug-centric approach Market Size
-
-
4.1.6 North America Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
4.1.6.1 North America Disease-centric approach Sales Volume
-
4.1.6.2 North America Target-centric approach Sales Volume
-
4.1.6.3 North America Drug-centric approach Sales Volume
-
-
4.1.7 North America Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
4.1.7.1 North America Oncology Market Size
-
4.1.7.2 North America CNS Diseases Market Size
-
4.1.7.3 North America Neurodegenerative Diseases Market Size
-
4.1.7.4 North America Others (Rare Disorders Market Size
-
4.1.7.5 North America etc.) Market Size
-
-
4.1.8 North America Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
4.1.8.1 North America Oncology Sales Volume
-
4.1.8.2 North America CNS Diseases Sales Volume
-
4.1.8.3 North America Neurodegenerative Diseases Sales Volume
-
4.1.8.4 North America Others (Rare Disorders Sales Volume
-
4.1.8.5 North America etc.) Sales Volume
-
-
4.1.9 North America Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
4.1.9.1 North America Hospitals & Clinics Market Size
-
4.1.9.2 North America Ambulatory Surgery Diseases Market Size
-
4.1.9.3 North America Others (Research Institutes Market Size
-
4.1.9.4 North America etc.) Market Size
-
-
4.1.10 North America Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
4.1.10.1 North America Hospitals & Clinics Sales Volume
-
4.1.10.2 North America Ambulatory Surgery Diseases Sales Volume
-
4.1.10.3 North America Others (Research Institutes Sales Volume
-
4.1.10.4 North America etc.) Sales Volume
-
-
This chapter will help you gain Europe Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review Europe Drug Repurposing Market Split by various segments and Country Split.
Chapter 5 Europe Market Analysis
-
5.1 Europe Drug Repurposing Market Outlook
-
5.1.1 Europe Drug Repurposing Market Size 2022 - 2034
-
5.1.2 Europe Drug Repurposing Volume Market Sales 2022 - 2034
-
5.1.3 Europe Drug Repurposing Market Size By Country 2022 - 2034
-
5.1.4 Europe Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
5.1.5 Europe Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
5.1.5.1 Europe Disease-centric approach Market Size
-
5.1.5.2 Europe Target-centric approach Market Size
-
5.1.5.3 Europe Drug-centric approach Market Size
-
-
5.1.6 Europe Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
5.1.6.1 Europe Disease-centric approach Sales Volume
-
5.1.6.2 Europe Target-centric approach Sales Volume
-
5.1.6.3 Europe Drug-centric approach Sales Volume
-
-
5.1.7 Europe Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
5.1.7.1 Europe Oncology Market Size
-
5.1.7.2 Europe CNS Diseases Market Size
-
5.1.7.3 Europe Neurodegenerative Diseases Market Size
-
5.1.7.4 Europe Others (Rare Disorders Market Size
-
5.1.7.5 Europe etc.) Market Size
-
-
5.1.8 Europe Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
5.1.8.1 Europe Oncology Sales Volume
-
5.1.8.2 Europe CNS Diseases Sales Volume
-
5.1.8.3 Europe Neurodegenerative Diseases Sales Volume
-
5.1.8.4 Europe Others (Rare Disorders Sales Volume
-
5.1.8.5 Europe etc.) Sales Volume
-
-
5.1.9 Europe Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
5.1.9.1 Europe Hospitals & Clinics Market Size
-
5.1.9.2 Europe Ambulatory Surgery Diseases Market Size
-
5.1.9.3 Europe Others (Research Institutes Market Size
-
5.1.9.4 Europe etc.) Market Size
-
-
5.1.10 Europe Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
5.1.10.1 Europe Hospitals & Clinics Sales Volume
-
5.1.10.2 Europe Ambulatory Surgery Diseases Sales Volume
-
5.1.10.3 Europe Others (Research Institutes Sales Volume
-
5.1.10.4 Europe etc.) Sales Volume
-
-
This chapter will help you gain Asia Pacific Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review Asia Pacific Drug Repurposing Market Split by various segments and Country Split.
Chapter 6 Asia Pacific Market Analysis
-
6.1 Asia Pacific Drug Repurposing Market Outlook
-
6.1.1 Asia Pacific Drug Repurposing Market Size 2022 - 2034
-
6.1.2 Asia Pacific Drug Repurposing Volume Market Sales 2022 - 2034
-
6.1.3 Asia Pacific Drug Repurposing Market Size By Country 2022 - 2034
-
6.1.4 Asia Pacific Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
6.1.5 Asia Pacific Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
6.1.5.1 Asia Pacific Disease-centric approach Market Size
-
6.1.5.2 Asia Pacific Target-centric approach Market Size
-
6.1.5.3 Asia Pacific Drug-centric approach Market Size
-
-
6.1.6 Asia Pacific Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
6.1.6.1 Asia Pacific Disease-centric approach Sales Volume
-
6.1.6.2 Asia Pacific Target-centric approach Sales Volume
-
6.1.6.3 Asia Pacific Drug-centric approach Sales Volume
-
-
6.1.7 Asia Pacific Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
6.1.7.1 Asia Pacific Oncology Market Size
-
6.1.7.2 Asia Pacific CNS Diseases Market Size
-
6.1.7.3 Asia Pacific Neurodegenerative Diseases Market Size
-
6.1.7.4 Asia Pacific Others (Rare Disorders Market Size
-
6.1.7.5 Asia Pacific etc.) Market Size
-
-
6.1.8 Asia Pacific Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
6.1.8.1 Asia Pacific Oncology Sales Volume
-
6.1.8.2 Asia Pacific CNS Diseases Sales Volume
-
6.1.8.3 Asia Pacific Neurodegenerative Diseases Sales Volume
-
6.1.8.4 Asia Pacific Others (Rare Disorders Sales Volume
-
6.1.8.5 Asia Pacific etc.) Sales Volume
-
-
6.1.9 Asia Pacific Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
6.1.9.1 Asia Pacific Hospitals & Clinics Market Size
-
6.1.9.2 Asia Pacific Ambulatory Surgery Diseases Market Size
-
6.1.9.3 Asia Pacific Others (Research Institutes Market Size
-
6.1.9.4 Asia Pacific etc.) Market Size
-
-
6.1.10 Asia Pacific Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
6.1.10.1 Asia Pacific Hospitals & Clinics Sales Volume
-
6.1.10.2 Asia Pacific Ambulatory Surgery Diseases Sales Volume
-
6.1.10.3 Asia Pacific Others (Research Institutes Sales Volume
-
6.1.10.4 Asia Pacific etc.) Sales Volume
-
-
This chapter will help you gain South America Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review South America Drug Repurposing Market Split by various segments and Country Split.
Chapter 7 South America Market Analysis
-
7.1 South America Drug Repurposing Market Outlook
-
7.1.1 South America Drug Repurposing Market Size 2022 - 2034
-
7.1.2 South America Drug Repurposing Volume Market Sales 2022 - 2034
-
7.1.3 South America Drug Repurposing Market Size By Country 2022 - 2034
-
7.1.4 South America Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
7.1.5 South America Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
7.1.5.1 South America Disease-centric approach Market Size
-
7.1.5.2 South America Target-centric approach Market Size
-
7.1.5.3 South America Drug-centric approach Market Size
-
-
7.1.6 South America Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
7.1.6.1 South America Disease-centric approach Sales Volume
-
7.1.6.2 South America Target-centric approach Sales Volume
-
7.1.6.3 South America Drug-centric approach Sales Volume
-
-
7.1.7 South America Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
7.1.7.1 South America Oncology Market Size
-
7.1.7.2 South America CNS Diseases Market Size
-
7.1.7.3 South America Neurodegenerative Diseases Market Size
-
7.1.7.4 South America Others (Rare Disorders Market Size
-
7.1.7.5 South America etc.) Market Size
-
-
7.1.8 South America Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
7.1.8.1 South America Oncology Sales Volume
-
7.1.8.2 South America CNS Diseases Sales Volume
-
7.1.8.3 South America Neurodegenerative Diseases Sales Volume
-
7.1.8.4 South America Others (Rare Disorders Sales Volume
-
7.1.8.5 South America etc.) Sales Volume
-
-
7.1.9 South America Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
7.1.9.1 South America Hospitals & Clinics Market Size
-
7.1.9.2 South America Ambulatory Surgery Diseases Market Size
-
7.1.9.3 South America Others (Research Institutes Market Size
-
7.1.9.4 South America etc.) Market Size
-
-
7.1.10 South America Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
7.1.10.1 South America Hospitals & Clinics Sales Volume
-
7.1.10.2 South America Ambulatory Surgery Diseases Sales Volume
-
7.1.10.3 South America Others (Research Institutes Sales Volume
-
7.1.10.4 South America etc.) Sales Volume
-
-
This chapter will help you gain Middle East Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review Middle East Drug Repurposing Market Split by various segments and Country Split.
Chapter 8 Middle East Market Analysis
-
8.1 Middle East Drug Repurposing Market Outlook
-
8.1.1 Middle East Drug Repurposing Market Size 2022 - 2034
-
8.1.2 Middle East Drug Repurposing Volume Market Sales 2022 - 2034
-
8.1.3 Middle East Drug Repurposing Market Size By Country 2022 - 2034
-
8.1.4 Middle East Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
8.1.5 Middle East Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
8.1.5.1 Middle East Disease-centric approach Market Size
-
8.1.5.2 Middle East Target-centric approach Market Size
-
8.1.5.3 Middle East Drug-centric approach Market Size
-
-
8.1.6 Middle East Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
8.1.6.1 Middle East Disease-centric approach Sales Volume
-
8.1.6.2 Middle East Target-centric approach Sales Volume
-
8.1.6.3 Middle East Drug-centric approach Sales Volume
-
-
8.1.7 Middle East Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
8.1.7.1 Middle East Oncology Market Size
-
8.1.7.2 Middle East CNS Diseases Market Size
-
8.1.7.3 Middle East Neurodegenerative Diseases Market Size
-
8.1.7.4 Middle East Others (Rare Disorders Market Size
-
8.1.7.5 Middle East etc.) Market Size
-
-
8.1.8 Middle East Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
8.1.8.1 Middle East Oncology Sales Volume
-
8.1.8.2 Middle East CNS Diseases Sales Volume
-
8.1.8.3 Middle East Neurodegenerative Diseases Sales Volume
-
8.1.8.4 Middle East Others (Rare Disorders Sales Volume
-
8.1.8.5 Middle East etc.) Sales Volume
-
-
8.1.9 Middle East Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
8.1.9.1 Middle East Hospitals & Clinics Market Size
-
8.1.9.2 Middle East Ambulatory Surgery Diseases Market Size
-
8.1.9.3 Middle East Others (Research Institutes Market Size
-
8.1.9.4 Middle East etc.) Market Size
-
-
8.1.10 Middle East Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
8.1.10.1 Middle East Hospitals & Clinics Sales Volume
-
8.1.10.2 Middle East Ambulatory Surgery Diseases Sales Volume
-
8.1.10.3 Middle East Others (Research Institutes Sales Volume
-
8.1.10.4 Middle East etc.) Sales Volume
-
-
This chapter will help you gain Middle East Market Analysis of Drug Repurposing. Further deep in this chapter, you will be able to review Middle East Drug Repurposing Market Split by various segments and Country Split.
Chapter 9 Africa Market Analysis
-
9.1 Africa Drug Repurposing Market Outlook
-
9.1.1 Africa Drug Repurposing Market Size 2022 - 2034
-
9.1.2 Africa Drug Repurposing Volume Market Sales 2022 - 2034
-
9.1.3 Africa Drug Repurposing Market Size By Country 2022 - 2034
-
9.1.4 Africa Drug Repurposing Volume Market Sales By Country 2022 - 2034
-
9.1.5 Africa Drug Repurposing Market Size by By Approach Type Outlook: 2022 - 2034
-
9.1.5.1 Africa Disease-centric approach Market Size
-
9.1.5.2 Africa Target-centric approach Market Size
-
9.1.5.3 Africa Drug-centric approach Market Size
-
-
9.1.6 Africa Drug Repurposing Volume Market Sales by By Approach Type Outlook: 2022 - 2034
-
9.1.6.1 Africa Disease-centric approach Sales Volume
-
9.1.6.2 Africa Target-centric approach Sales Volume
-
9.1.6.3 Africa Drug-centric approach Sales Volume
-
-
9.1.7 Africa Drug Repurposing Market Size by By Disease Indication Outlook: 2022 - 2034
-
9.1.7.1 Africa Oncology Market Size
-
9.1.7.2 Africa CNS Diseases Market Size
-
9.1.7.3 Africa Neurodegenerative Diseases Market Size
-
9.1.7.4 Africa Others (Rare Disorders Market Size
-
9.1.7.5 Africa etc.) Market Size
-
-
9.1.8 Africa Drug Repurposing Volume Market Sales by By Disease Indication Outlook: 2022 - 2034
-
9.1.8.1 Africa Oncology Sales Volume
-
9.1.8.2 Africa CNS Diseases Sales Volume
-
9.1.8.3 Africa Neurodegenerative Diseases Sales Volume
-
9.1.8.4 Africa Others (Rare Disorders Sales Volume
-
9.1.8.5 Africa etc.) Sales Volume
-
-
9.1.9 Africa Drug Repurposing Market Size by By End-user Outlook: 2022 - 2034
-
9.1.9.1 Africa Hospitals & Clinics Market Size
-
9.1.9.2 Africa Ambulatory Surgery Diseases Market Size
-
9.1.9.3 Africa Others (Research Institutes Market Size
-
9.1.9.4 Africa etc.) Market Size
-
-
9.1.10 Africa Drug Repurposing Volume Market Sales by By End-user Outlook: 2022 - 2034
-
9.1.10.1 Africa Hospitals & Clinics Sales Volume
-
9.1.10.2 Africa Ambulatory Surgery Diseases Sales Volume
-
9.1.10.3 Africa Others (Research Institutes Sales Volume
-
9.1.10.4 Africa etc.) Sales Volume
-
-
This chapter provides an in-depth analysis of the market share among key competitors of Drug Repurposing. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 10 Competitor Analysis (Subject to Data Availability (Private Players))
-
10.1 Top Competitors Analysis
-
10.1.1 Global Drug Repurposing Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
10.1.2 Global Drug Repurposing Market Volume and Share by Key Players
-
10.1.3 Top Players Ranking 2024
-
10.1.4 New Product Launch Analysis
-
10.1.5 Industry Mergers and Acquisition Analysis
-
-
10.2 Company Profile (Data Subject to Availability) Sample Format
-
10.2.1 Algernon Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.1.2 Business Overview
-
10.2.1.3 Financials (Subject to data availability)
-
10.2.1.4 R&D Investment (Subject to data availability)
-
10.2.1.5 Product Types Specification
-
10.2.1.6 Business Strategy
-
10.2.1.7 Recent Developments
-
10.2.1.8 Management Change
-
10.2.1.9 S.W.O.T Analysis
-
-
10.2.2 Biovista Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.2.2 Business Overview
-
10.2.2.3 Financials (Subject to data availability)
-
10.2.2.4 R&D Investment (Subject to data availability)
-
10.2.2.5 Product Types Specification
-
10.2.2.6 Business Strategy
-
10.2.2.7 Recent Developments
-
10.2.2.8 Management Change
-
10.2.2.9 S.W.O.T Analysis
-
-
10.2.3 Celentyx Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.3.2 Business Overview
-
10.2.3.3 Financials (Subject to data availability)
-
10.2.3.4 R&D Investment (Subject to data availability)
-
10.2.3.5 Product Types Specification
-
10.2.3.6 Business Strategy
-
10.2.3.7 Recent Developments
-
10.2.3.8 Management Change
-
10.2.3.9 S.W.O.T Analysis
-
-
10.2.4 ChemBio Discovery Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.4.2 Business Overview
-
10.2.4.3 Financials (Subject to data availability)
-
10.2.4.4 R&D Investment (Subject to data availability)
-
10.2.4.5 Product Types Specification
-
10.2.4.6 Business Strategy
-
10.2.4.7 Recent Developments
-
10.2.4.8 Management Change
-
10.2.4.9 S.W.O.T Analysis
-
-
10.2.5 Chord Therapeutics SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.5.2 Business Overview
-
10.2.5.3 Financials (Subject to data availability)
-
10.2.5.4 R&D Investment (Subject to data availability)
-
10.2.5.5 Product Types Specification
-
10.2.5.6 Business Strategy
-
10.2.5.7 Recent Developments
-
10.2.5.8 Management Change
-
10.2.5.9 S.W.O.T Analysis
-
-
10.2.6 Excelra
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.6.2 Business Overview
-
10.2.6.3 Financials (Subject to data availability)
-
10.2.6.4 R&D Investment (Subject to data availability)
-
10.2.6.5 Product Types Specification
-
10.2.6.6 Business Strategy
-
10.2.6.7 Recent Developments
-
10.2.6.8 Management Change
-
10.2.6.9 S.W.O.T Analysis
-
-
10.2.7 Fios Genomics Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.7.2 Business Overview
-
10.2.7.3 Financials (Subject to data availability)
-
10.2.7.4 R&D Investment (Subject to data availability)
-
10.2.7.5 Product Types Specification
-
10.2.7.6 Business Strategy
-
10.2.7.7 Recent Developments
-
10.2.7.8 Management Change
-
10.2.7.9 S.W.O.T Analysis
-
-
10.2.8 Lantern Pharma Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.8.2 Business Overview
-
10.2.8.3 Financials (Subject to data availability)
-
10.2.8.4 R&D Investment (Subject to data availability)
-
10.2.8.5 Product Types Specification
-
10.2.8.6 Business Strategy
-
10.2.8.7 Recent Developments
-
10.2.8.8 Management Change
-
10.2.8.9 S.W.O.T Analysis
-
-
10.2.9 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.9.2 Business Overview
-
10.2.9.3 Financials (Subject to data availability)
-
10.2.9.4 R&D Investment (Subject to data availability)
-
10.2.9.5 Product Types Specification
-
10.2.9.6 Business Strategy
-
10.2.9.7 Recent Developments
-
10.2.9.8 Management Change
-
10.2.9.9 S.W.O.T Analysis
-
-
10.2.10 Paradigm Biopharmaceuticals Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.10.2 Business Overview
-
10.2.10.3 Financials (Subject to data availability)
-
10.2.10.4 R&D Investment (Subject to data availability)
-
10.2.10.5 Product Types Specification
-
10.2.10.6 Business Strategy
-
10.2.10.7 Recent Developments
-
10.2.10.8 Management Change
-
10.2.10.9 S.W.O.T Analysis
-
-
10.2.11 Predictive Oncology
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.11.2 Business Overview
-
10.2.11.3 Financials (Subject to data availability)
-
10.2.11.4 R&D Investment (Subject to data availability)
-
10.2.11.5 Product Types Specification
-
10.2.11.6 Business Strategy
-
10.2.11.7 Recent Developments
-
10.2.11.8 Management Change
-
10.2.11.9 S.W.O.T Analysis
-
-
10.2.12 Segue Therapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.12.2 Business Overview
-
10.2.12.3 Financials (Subject to data availability)
-
10.2.12.4 R&D Investment (Subject to data availability)
-
10.2.12.5 Product Types Specification
-
10.2.12.6 Business Strategy
-
10.2.12.7 Recent Developments
-
10.2.12.8 Management Change
-
10.2.12.9 S.W.O.T Analysis
-
-
10.2.13 LLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.13.2 Business Overview
-
10.2.13.3 Financials (Subject to data availability)
-
10.2.13.4 R&D Investment (Subject to data availability)
-
10.2.13.5 Product Types Specification
-
10.2.13.6 Business Strategy
-
10.2.13.7 Recent Developments
-
10.2.13.8 Management Change
-
10.2.13.9 S.W.O.T Analysis
-
-
10.2.14 Teva Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
10.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
10.2.14.2 Business Overview
-
10.2.14.3 Financials (Subject to data availability)
-
10.2.14.4 R&D Investment (Subject to data availability)
-
10.2.14.5 Product Types Specification
-
10.2.14.6 Business Strategy
-
10.2.14.7 Recent Developments
-
10.2.14.8 Management Change
-
10.2.14.9 S.W.O.T Analysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 11 Qualitative Analysis (Subject to Data Availability)
-
11.1 Market Drivers
-
11.2 Market Restraints
-
11.3 Market Trends
-
11.4 Market Opportunity
-
11.5 Technological Road Map (Subject to Data Availability)
-
11.6 Product Life Cycle (Subject to Data Availability)
-
11.7 Customer and Buyer Behavior Analysis
-
11.7.1 Consumer Demographics and Target Audience Assessment
-
11.7.2 Consumer Purchase Behavior and Demand Assessment
-
11.7.3 Consumer Pricing Dynamics and Affordability Assessment
-
11.7.4 Digital Consumer Engagement and Online Adoption Analysis
-
11.7.5 Future Consumption Trends and Demand Evolution Analysis
-
11.7.6 Enterprise Procurement & Purchasing Behavior Analysis
-
11.7.7 Buyer Decision-Making & Purchase Influence Assessment
-
11.7.8 Customer Expectations & Service Experience Evaluation
-
11.7.9 Vendor Selection & Supplier Preference Analysis
-
11.7.10 Customer Retention & Loyalty Strategy Assessment
-
11.7.11 Pricing Sensitivity & Value Perception Analysis
-
11.7.12 Customer Segmentation & Demand Pattern Analysis
-
11.7.13 Relationship Management & Strategic Partnership Trends
-
-
11.8 Market Attractiveness Analysis
-
11.9 PESTEL Analysis
-
11.9.1 Political Factors
-
11.9.2 Economic Factors
-
11.9.3 Social Factors
-
11.9.4 Technological Factors
-
11.9.5 Legal Factors
-
11.9.6 Environmental Factors
-
-
11.10 Industrial Chain Analysis (Subject to Data Availability)
-
11.10.1 Industry Chain Analysis
-
11.10.2 Manufacturing Cost Analysis
-
11.10.3 Supply Side Analysis
-
11.10.3.1 Raw Material Analysis
-
11.10.3.2 Raw Material Procurement Analysis
-
11.10.3.3 Raw Material Price Trend Analysis
-
-
-
11.11 Porter’s Five Forces Analysis
-
11.11.1 Bargaining Power of Suppliers
-
11.11.2 Bargaining Power of Buyers
-
11.11.3 Threat of New Entrants
-
11.11.4 Threat of Substitutes
-
11.11.5 Degree of Competition
-
-
11.12 Patent Analysis (Subject to Data Availability)
-
11.13 ESG Analysis
Segmentation By Approach Type Outlook: Analysis 2019 -2031, will provide market size split by By Approach Type Outlook:. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by By Approach Type Outlook: Analysis 2022 - 2034
-
12.1 Disease-centric approach
-
12.1.1 Global Drug Repurposing Revenue Market Size and Share by Disease-centric approach 2022 - 2034
-
12.1.2 Global Drug Repurposing Volume Market Sales by Disease-centric approach 2022 - 2034
-
-
12.2 Target-centric approach
-
12.2.1 Global Drug Repurposing Revenue Market Size and Share by Target-centric approach 2022 - 2034
-
12.2.2 Global Drug Repurposing Volume Market Sales by Target-centric approach 2022 - 2034
-
-
12.3 Drug-centric approach
-
12.3.1 Global Drug Repurposing Revenue Market Size and Share by Drug-centric approach 2022 - 2034
-
12.3.2 Global Drug Repurposing Volume Market Sales by Drug-centric approach 2022 - 2034
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by By Disease Indication Outlook: Analysis 2022 - 2034
-
13.1 Oncology
-
13.1.1 Global Drug Repurposing Revenue Market Size and Share by Oncology 2022 - 2034
-
13.1.2 Global Drug Repurposing Volume Market Sales by Oncology 2022 - 2034
-
-
13.2 CNS Diseases
-
13.2.1 Global Drug Repurposing Revenue Market Size and Share by CNS Diseases 2022 - 2034
-
13.2.2 Global Drug Repurposing Volume Market Sales by CNS Diseases 2022 - 2034
-
-
13.3 Neurodegenerative Diseases
-
13.3.1 Global Drug Repurposing Revenue Market Size and Share by Neurodegenerative Diseases 2022 - 2034
-
13.3.2 Global Drug Repurposing Volume Market Sales by Neurodegenerative Diseases 2022 - 2034
-
-
13.4 Others (Rare Disorders
-
13.4.1 Global Drug Repurposing Revenue Market Size and Share by Others (Rare Disorders 2022 - 2034
-
13.4.2 Global Drug Repurposing Volume Market Sales by Others (Rare Disorders 2022 - 2034
-
-
13.5 etc.)
-
13.5.1 Global Drug Repurposing Revenue Market Size and Share by etc.) 2022 - 2034
-
13.5.2 Global Drug Repurposing Volume Market Sales by etc.) 2022 - 2034
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by By End-user Outlook: Analysis 2022 - 2034
-
14.1 Hospitals & Clinics
-
14.1.1 Global Drug Repurposing Revenue Market Size and Share by Hospitals & Clinics 2022 - 2034
-
14.1.2 Global Drug Repurposing Volume Market Sales by Hospitals & Clinics 2022 - 2034
-
-
14.2 Ambulatory Surgery Diseases
-
14.2.1 Global Drug Repurposing Revenue Market Size and Share by Ambulatory Surgery Diseases 2022 - 2034
-
14.2.2 Global Drug Repurposing Volume Market Sales by Ambulatory Surgery Diseases 2022 - 2034
-
-
14.3 Others (Research Institutes
-
14.3.1 Global Drug Repurposing Revenue Market Size and Share by Others (Research Institutes 2022 - 2034
-
14.3.2 Global Drug Repurposing Volume Market Sales by Others (Research Institutes 2022 - 2034
-
-
14.4 etc.)
-
14.4.1 Global Drug Repurposing Revenue Market Size and Share by etc.) 2022 - 2034
-
14.4.2 Global Drug Repurposing Volume Market Sales by etc.) 2022 - 2034
-
Chapter 15 Drug Repurposing Price Trend Analysis
-
15.1 Global Drug Repurposing Price Trend Analysis
-
15.2 Global Drug Repurposing Price Trend Analysis By Region
-
15.3 North America Drug Repurposing Price Trend Analysis
-
15.4 Europe Drug Repurposing Price Trend Analysis
-
15.5 Asia Pacific Drug Repurposing Price Trend Analysis
-
15.6 South America Drug Repurposing Price Trend Analysis
-
15.7 Middle East Drug Repurposing Price Trend Analysis
-
15.8 Africa Drug Repurposing Price Trend Analysis
-
15.9 Drug Repurposing Price Trend Analysis By By Approach Type Outlook:
-
15.9.1 Global Drug Repurposing Price Trend Analysis By By Approach Type Outlook:
-
Chapter 16 Gap Analysis
-
16.1 Company Gap Assessment Analysis
-
16.2 Product & Service Portfolio Gap Analysis
-
16.3 Demand-Supply Imbalance Analysis
-
16.4 Market Opportunity & Unmet Needs Analysis
-
16.5 Technology Adoption & Digital Transformation Gap Analysis
-
16.6 Operational Efficiency & Process Gap Analysis
-
16.7 Infrastructure & Capacity Gap Analysis
-
16.8 Geographic Coverage & Distribution Gap Analysis
-
16.9 Investment Opportunity & Funding Gap Analysis
-
16.10 Pricing Structure & Margin Gap Analysis
-
16.11 Innovation & R&D Capability Gap Analysis
-
16.12 Policy, Compliance & Regulatory Gap Analysis
-
16.13 Customer Experience & Expectation Gap Analysis
-
16.14 Future Growth Opportunity Gap Analysis
-
16.15 Market Accessibility & Penetration Gap Analysis
Chapter 17 Strategy Analysis
-
17.1 Strategic Commercialization & Pricing Assessment
Chapter 18 Profitability and Gross Margin Analysis
-
18.1 Gross Margin Overview and Industry Profitability Trends
-
18.2 Regional Gross Margin Performance Analysis
-
18.3 Supply Chain and Distribution Impact on Gross Margins
-
18.4 Pricing Strategy and Value-Added Margin Assessment
-
18.5 Key Factors Influencing Gross Margin Variability
-
18.6 Future Gross Margin Outlook and Profitability Trends
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Drug Repurposing market
Chapter 19 Research Findings
-
19.1 Key Takeaways
-
19.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
19.3 Assumptions and Acronyms
Chapter 20 Research Methodology and Sources
-
20.1 Primary Data Collection
-
20.1.1 Steps for Primary Data Collection
-
20.1.1.1 Identification of KOL
-
-
20.1.2 Backward Integration
-
20.1.3 Forward Integration
-
20.1.4 How Primary Research Help Us
-
20.1.5 Modes of Primary Research
-
-
20.2 Secondary Research
-
20.2.1 How Secondary Research Help Us
-
20.2.2 Sources of Secondary Research
-
-
20.3 Data Validation
-
20.3.1 Data Triangulation
-
20.3.2 Top Down & Bottom Up Approach
-
20.3.3 Cross check KOL Responses with Secondary Data
-
-
20.4 Data Representation
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Cognitive's Full Truth Proprietary Research Methodology Implemented by Supriya Yadav and Team
1 Data Gathering
-
1.1 Research Design & Problem Structuring
-
1.1.1 Identification of Research Objectives
-
1.1.2 Market, Region, and Timeframe Definition
-
1.1.3 Problem Decomposition & Hypothesis Development
-
1.1.4 Mapping Data Requirements & Analytical Framework
-
-
1.2 Data Architecture & Multi-Source Intelligence
-
1.2.1 Primary Research
-
1.2.1.1 Manufacturers, distributors, and traders
-
1.2.1.2 Procurement managers and industry buyers
-
1.2.1.3 Technology providers and innovators
-
1.2.1.4 Regulators and policy authorities
-
1.2.1.5 Subject-matter experts and consultants
-
1.2.1.6 End users across both B2B and B2C segments
-
-
1.2.2 Secondary Research
-
1.2.2.1 Public data sources
-
1.2.2.2 Paid Data Sources
-
-
1.2.3 Internal Knowledge Systems
-
2 Data Validation
-
2.1 Market Engineering & Quantitative Modelling
-
2.1.1 Market Sizing and Forecasting Approach
-
2.1.1.1 Market Sizing Techniques
-
2.1.1.2 Forecasting Models
-
-
-
2.2 Economic Modelling Framework
-
2.2.1 Cost Structure & Value Chain Economics
-
2.2.2 Demand & Price Elasticity Analysis
-
2.2.3 Supply–Demand Balance Assessment
-
2.2.4 Economic Impact Assessment
-
-
2.3 Industry Structure, Competition & Technology Analysis
-
2.3.1 Tools and Approaches Applied
-
-
2.4 Validation & Sensitivity Analysis
-
2.5 Insight Development & Recommendations
-
2.6 Transparent Documentation
3 Data Presentation
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for our full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants your team direct access to our lead analysts for bespoke strategic consultation.
Latest News about Drug Repurposing Market
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main